Page 222 - Pagetit

6. CONCURRENT DISORDERS

Lloyd KG et al. (1989) The GABAergic hypothesis of depression. Progress in
Neuropsychopharmacology and Biological Psychiatry, 13:341–351.
Lodge D, Johnson KM (1990) Noncompetitive excitatory amino acid receptor
antagonists. Trends in Pharmacological Sciences, 11:81–86.
Luisada PV (1978) The phencyclidine psychosis: phenomenology and treatment.
NIDA Research Monograph, 21:241–253.
Lysaker P et al. (1994) Relationship of positive and negative symptoms to cocaine
abuse in schizophrenia. Journal of Nervous and Mental Disorders, 182:109–112.
McEvoy JP, Freudenreich O, Wilson WH (1999) Smoking and therapeutic response
to clozapine in patients with schizophrenia. Biological Psychiatry, 46:125–129.
McEvoy J et al. (1995) Clozapine decreases smoking in patients with chronic
schizophrenia. Biological Psychiatry, 37:550–552.
McGrath PJ et al. (1996) Imipramine treatment of alcoholics with primary
depression: a placebo-controlled clinical trial. Archives of General Psychiatry,
53:232–240.
Malhotra AK et al. (1997) Ketamine-induced exacerbation of psychotic symptoms
and cognitive impairment in neuroleptic-free schizophrenics. Neuropsychophar-
macology, 17:141–150.
Manoach DS et al. (2000) Schizophrenic subjects show aberrant fMRI activation
of dorsolateral prefrontal cortex and basal ganglia during working memory
performance. Biological Psychiatry, 48:99–109.
Mansvelder HD, McGehee DS (2000) Long-term potentiation of excitatory inputs
to brain reward areas by nicotine. Neuron, 27:349–357.
Marder SR, Wirshing WC, Van Putten T (1991) Drug treatment of schizophrenia:
overview of recent research. Schizophrenia Research, 4:81–90.
Markou A, Kosten TR, Koob GF (1998) Neurobiological similarities in depression
and drug dependence: a self-medication hypothesis. Neuropsychopharmacology,
18:135–174.
Markou A et al. (1993) Animal models of drug craving. Psychopharmacology,
112:163–182.
Marshall DL, Redfern PH, Wonnacott S (1997) Presynaptic nicotinic modulation
of dopamine release in the three ascending pathways studied by in vivo
microdialysis: comparison of naïve and chronic nicotine-treated rats. Journal of
Neurochemistry, 68:1511–1519.
Mason BJ et al. (1996) A double-blind, placebo-controlled trial of desipramine
for primary alcohol dependence stratified on the presence or absence of major
depression. Journal of the American Medical Association, 275:761–767.
Masterson E, O’Shea B (1984) Smoking and malignancy in schizophrenia. British
Journal of Psychiatry, 145:429–432.
Mauskopf JA et al. (1999) Annual health outcomes and treatment costs for
schizophrenia populations. Journal of Clinical Psychiatry, 60 Suppl: S14–S19.
Meltzer HY (1999) Outcome in schizophrenia: beyond symptom reduction.
Journal of Clinical Psychiatry, 60 Suppl: S3–S7.

201

Chapter_6 201 19.1.2004, 11:49